Use of PRG4 as an anti-inflammatory agent
US11717557B2 · kind B2 · utility
0Cited by
32References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 8, 2021 |
| Grant date | Aug 8, 2023 |
| Priority date | — |
| Expiry date | Apr 15, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-κB translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.